Libby Duignan – Phage Therapy for Antibiotic-Resistant Bacteria: Overcoming Manufacturing Barriers in the UK
Libby Duignan // CPI, HVM Catapult // Healthcare & Wellbeing
This project, in collaboration with CPI (HVM Catapult) explores the growing global threat of antibiotic resistance – a major healthcare challenge. Between 2025 and 2050, antimicrobial resistance is projected to cause an estimated 39 million deaths (UK data source pending confirmation). One promising alternative to antibiotics is phage therapy, which uses viruses (phages) to target and destroy antibiotic-resistant bacteria. However, in the UK, significant barriers remain around phage manufacturing.
Download the full case study here